Ionis Pharmaceuticals, Inc.

Quotes of biotech Ionis Pharmaceuticals jumped 35% in a single day after it announced a successful trial of a drug that reduces triglyceride levels in the blood and prevents cases of acute pancreatitis. Analysts were positive about the results. The company, which is known for its Spinraza drug for spinal muscular atrophy, could see its shares rise another 40%, according to some analysts' models.&nbsp;

Biotech Ionis Pharmaceuticals surges 35% after upbeat trial of triglyceride drug

Voyager Technologies, Inc.

Redwire Corporation

MDA Space Ltd.

Intuitive Machines, Inc.

By 2035, the global space economy, from satellite communications to AI-driven analytics, will reach $1.8 trillion, according to <a href="https://www.mckinsey.com/featured-insights/themes/the-space-economy-is-projected-to-reach-1-8-trillion-by-2035">projections</a> by McKinsey and the World Economic Forum in Davos. Yet while most eyes are on Elon Musk’s SpaceX launches or visions of colonizing Mars, the real money is often being made in the less glamorous corners of the industry. One such player is the small-cap Redwire, the Motley Fool <a href="https://www.fool.com/investing/2025/06/25/7-space-stocks-id-buy-without-hesitation/">highlights</a>&nbsp;in a list of seven space stocks to buy "without hesitation." Wall Street <a href="https://www.marketwatch.com/investing/stock/rdw/analystestimates?mod=mw_quote_tab">expects </a>Redwire&nbsp;stock to double, even though the company remains unprofitable.

From space medicine to Mars colony: Redwire believed to offer triple-digit upside

Sarepta Therapeutics, Inc.

Shares of Sarepta Therapeutics, a small-cap developer of genetic medicines to treat rare neuromuscular and central nervous system diseases, soared 14% yesterday, July 29. The driver of the gains was the announcement that U.S. health regulators had authorized the biotech to resume shipments of its gene therapy that accounts for the majority of its revenue. Still, analysts&nbsp;caution that sales momentum will need to be maintained for the company to make a looming debt repayment.&nbsp;

Shares in biotech Sarepta soar after FDA allows shipments of Elevidys to resume


Telomir Pharmaceuticals, Inc.

Zacks says take a look at the stock ahead of human trials of Telomir's primary drug early next year



Zacks reiterates recommendation on anti-aging drugmaker Telomir despite 47% YTD loss

Viking Therapeutics, Inc.

Novo Nordisk A/S

Eli Lilly and Company

Viking Therapeutics, a clinical-stage biotech developing, among other things, an oral weight-loss drug, has reported a net loss a third bigger than the market expected and is set to further increase R&amp;D spending. That said, the company is still considered a leading small-/mid-sized player in the weight-loss drug market and could pose a threat to Novo Nordisk and Eli Lilly with their injected therapies, Wall Street believes.&nbsp;

Oral weight-loss drugmaker Viking reports widening loss in 2Q, guides for higher R&D

Incyte Corporation

Jefferies Financial Group Inc.

ServiceTitan, Inc.

The companies operate in health care, tech and finance

Three sectors, three stocks: Freedom gives mid-cap ideas for next 12 months

China has entered the race in the market of weight loss drugs: several companies from China have presented their products that may become competitors to Ozempic, Mounjaro and other hits from Novo Nordisk and Eli Lilly. The first of these received regulatory approval in June. In general, Chinese biotech has survived the prolonged "nuclear winter" and is now actively developing. What should an investor know about it?

The end of nuclear winter and tens of percent growth: how China is growing its pharma giants


Candel Therapeutics, Inc.

Freedom Broker has initiated on Candel Therapeutics, which&nbsp;develops immunotherapies for cancer patients, and estimates the stock has upside of more than 100%. The company has low debt and a large cash pile to finance operations, Freedom Broker points out.

Freedom Broker initiates with 'buy' on cancer therapy developer Candel Therapeutics

Freedom Broker has issued a trade idea on the biotech Viking Therapeutics. The company is expected to present fresh data from clinical trials of its main weight-loss drug, and historically, as Freedom Broker points out, the stock rises ahead of these events.

Freedom Broker says buy weight-loss drugmaker Viking ahead of 2H data releases

ProKidney Corp.

Biotech ProKidney, which develops a cell therapy platform for the treatment of multiple chronic kidney diseases, rose sixfold yesterday, July 8, to reach a market capitalization of $1.8 billion. The trigger was successful clinical trial results of its drug, but analysts are cautious.&nbsp;

Biotech ProKidney soars 500% after positive trial results, but analysts are cautious

Ocugen, Inc.

Carisma Therapeutics, Inc.

Gene and cell therapy biotech Ocugen has <a href="https://finance.yahoo.com/news/carisma-therapeutics-orthocellix-enter-definitive-113000554.html">agreed</a> to a merger with Carisma Therapeutics, a tiny <a href="https://carismatx.com/">developer</a> of novel therapies for fibrosis and cancer. Ocugen will transfer its regenerative medicine division and in return will get 90% of the new company. Noble Capital Markets&nbsp;<a href="https://www.channelchek.com/news-channel/ocugen-ocgn-merger-agreement-moves-neocart-into-a-new-company">sees</a>&nbsp;more than 670% upside for Ocugen.&nbsp;

Biotech Ocugen to spin off regenerative medicine division; Noble confirms 670% upside

SS Innovations International, Inc.

SS Innovations, a developer of surgical robotic technologies, soared 42% yesterday, June 18. That is how investors reacted to the news of the successful completion of its first robotic cardiac surgery in the Western Hemisphere. The stock has been trading on the Nasdaq for only about two months.

#Biotechnology: 19